{
  "id": 6400117,
  "title": "Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next",
  "url": "https://urgent.news/2026/09/09/eli-lillys-pipeline-in-2026-how-the-incretin-boom-is-funding-what",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-09T08:00:00.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/top-pharma-strategy/eli-lilly-pipeline-2026/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Kura Oncology spins out diabetes pipeline with $50M and Lilly's help",
        "url": "https://urgent.news/2026/09/09/kura-oncology-spins-out-diabetes-pipeline-with-50m-and-lillys-help",
        "published": "2026-09-09T11:00:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}